Atria Investments Inc Trims Stock Holdings in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)

Atria Investments Inc reduced its stake in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) by 22.2% during the 4th quarter, Holdings Channel reports. The institutional investor owned 37,295 shares of the company’s stock after selling 10,636 shares during the period. Atria Investments Inc’s holdings in Checkpoint Therapeutics were worth $119,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Geode Capital Management LLC increased its stake in Checkpoint Therapeutics by 41.2% during the third quarter. Geode Capital Management LLC now owns 427,651 shares of the company’s stock worth $958,000 after purchasing an additional 124,787 shares during the period. HB Wealth Management LLC increased its stake in Checkpoint Therapeutics by 96.9% during the fourth quarter. HB Wealth Management LLC now owns 153,560 shares of the company’s stock worth $513,000 after purchasing an additional 75,560 shares during the period. PVG Asset Management Corp increased its stake in Checkpoint Therapeutics by 9.2% during the third quarter. PVG Asset Management Corp now owns 149,870 shares of the company’s stock worth $336,000 after purchasing an additional 12,676 shares during the period. State Street Corp increased its stake in Checkpoint Therapeutics by 32.2% during the third quarter. State Street Corp now owns 94,424 shares of the company’s stock worth $212,000 after purchasing an additional 23,000 shares during the period. Finally, Walleye Capital LLC purchased a new stake in Checkpoint Therapeutics during the third quarter worth about $148,000. 22.00% of the stock is currently owned by hedge funds and other institutional investors.

Checkpoint Therapeutics Stock Performance

CKPT stock opened at $4.07 on Thursday. The company’s 50 day moving average price is $3.20 and its 200 day moving average price is $3.17. Checkpoint Therapeutics, Inc. has a fifty-two week low of $1.38 and a fifty-two week high of $4.50. The firm has a market capitalization of $198.75 million, a price-to-earnings ratio of -2.21 and a beta of 1.41.

Analyst Ratings Changes

A number of analysts have issued reports on CKPT shares. D. Boral Capital reiterated a “buy” rating and set a $4.80 price target (down from $9.00) on shares of Checkpoint Therapeutics in a research note on Monday, March 10th. Lake Street Capital restated a “hold” rating and set a $4.10 target price (down from $7.00) on shares of Checkpoint Therapeutics in a research note on Monday, March 10th. Finally, HC Wainwright restated a “neutral” rating and set a $4.10 target price on shares of Checkpoint Therapeutics in a research note on Tuesday, March 11th.

Insider Activity at Checkpoint Therapeutics

In related news, CFO William Garrett Gray sold 74,110 shares of the company’s stock in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $3.67, for a total value of $271,983.70. Following the completion of the transaction, the chief financial officer now directly owns 1,458,644 shares of the company’s stock, valued at $5,353,223.48. This represents a 4.84 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO James F. Oliviero III sold 10,331 shares of the company’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $3.15, for a total value of $32,542.65. Following the completion of the transaction, the chief executive officer now directly owns 3,775,019 shares of the company’s stock, valued at $11,891,309.85. This trade represents a 0.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 93,674 shares of company stock valued at $336,011 over the last three months. 2.10% of the stock is owned by corporate insiders.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.